Evidence map›Paper›PMID 36834585›Full record

ArticleInternational journal of molecular sciences2023

Flavonoids from

Wenna Zhou, Jian Ouyang, Na Hu, Honglun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Assessment of the biosafety profile ofWorld journal of cardiology · 2025
    Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wenna ZhouDepartment of Pharmaceutical Engineering, School of Life and Health Sciences, Huzhou College, Huzhou 313000, China.ORCID 0000-0001-6728-4122
Jian OuyangQinghai Provincial Key Laboratory of Tibetan Medicine Research and CAS Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Xining 810008, China.
Na HuQinghai Provincial Key Laboratory of Tibetan Medicine Research and CAS Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Xining 810008, China.
Honglun WangQinghai Provincial Key Laboratory of Tibetan Medicine Research and CAS Key Laboratory of Tibetan Medicine Research, Northwest Institute of Plateau Biology, Xining 810008, China.ORCID 0000-0002-9882-9604

Funding

National Sciences Foundation of China No.32000275 and No.31870333Public welfare applied research project of Huzhou science and technology Bureau No.2021GZ55Yantai ShuangBai Scholar Program, Innovation Platform for the Development and Construction of Special Project of Qinghai Province 2021-ZJ-T05Zhejiang Provincial Natural Science Foundation No. LQ20C020001
6 · The paper itself

Abstract

Doxorubicin (Dox) is one of the most frequently prescribed anti-cancer drugs. However, treatment with Dox is limited due to cumulative cardiotoxicity. 3-

Indexed as

HippophaeAdenosine TriphosphateAnimalsApoptosisCardiotoxicityCaspase 3DoxorubicinEndoribonucleasesFlavonoidsMitochondriaMolecular Docking SimulationMyocytes, CardiacProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktRatsReactive Oxygen SpeciesAdenosine TriphosphateCaspase 3DoxorubicinEndoribonucleasesFlavonoidsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktReactive Oxygen SpeciesdoxorubicinflavonoidsHippophae rhamnoides Linn.JNK-Sab-Ros

Identifiers

PMID36834585
PMCPMC9961788

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.